CRISPR-AsCas12a with crRNA-Free Collateral Cleavage Activity for Electrochemical Diagnosis of HER2-Positive Breast Cancer
ACS Sensors · 14.11.2026
DOI: 10.1021/acssensors.6c03688 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Sensors, online erschienen am 14.11.2026. Verfasst von Shuai Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medicine Research Institute, The First Affiliated Hospital with Nanjing Medical University, Nanjing210029, P. R. China. Die Arbeit nennt 39 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Collaborative Innovation Center for Tumor Individualization Program, First Affiliated Hospital, Nanjing Medical University.
Abstract (Originalsprache)
The CRISPR-Cas12a system has revolutionized molecular diagnostics; however, the strict requirement of crRNAs and target DNA for collateral cleavage activation restricts its flexibility in non-nucleic acid diagnostics. Herein, we demonstrate that AsCas12a exhibits an RNA-free collateral cleavage activity with the presence of manganese ions (Mn2+), which preferentially cleaves single-stranded DNA efficiently. Mechanistically, kinetic analyses reveal that AsCas12a exhibits a significantly higher binding affinity for Mn2+ than for magnesium ion (Mg2+), while molecular dynamics simulations suggest that Mn2+ coordination induces conformational changes to expose the RuvC endonuclease domain. Harnessing this unique property, an enzymatic cascade-amplified electrochemical biosensor integrating manganese nanoflowers is reported for the diagnosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. By equipping screen-printed gold electrodes with DNA reporters, this diagnostic tool enables high-precision HER2 quantification and successfully distinguishes various HER2-related cell lines. Furthermore, the biosensor has been extended to analyze HER2-positive exosomes, facilitating the dynamic tracking of serum exosome levels in tumor-bearing nude mice to evaluate therapeutic efficacy and accurately distinguish HER2-positive breast cancer patients in clinical samples. This RNA-free Cas12a system may provide new insights into CRISPR-based non-nucleic acid detection, emerging as a powerful tool for dynamic tumor monitoring and precision oncology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinical Medicine Research Institute, The First Affiliated Hospital with Nanjing Medical University, Nanjing210029, P. R. China.
- Department of Oncology, The First Affiliated Hospital with Nanjing Medical University, Nanjing210029, P. R. China.
- State Key Laboratory of Analytical Chemistry for Life Science, School of Life Sciences, Nanjing University, Nanjing210023, P. R. China.
- Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing210008, China.
- Center for Molecular Recognition and Biosensing, School of Life Sciences, Shanghai University, Shanghai200444, P. R. China.
ORCID-Profile: Shuai Wu, Genxi Li, Yongmei Yin
Förderung
- National Natural Science Foundation of China
- Collaborative Innovation Center for Tumor Individualization Program
- First Affiliated Hospital, Nanjing Medical University
- Jiangsu Province Hospital High level Talent Cultivation Program
- Jiangsu Province Hospital
Zitieren
APA
Wu, S., Xu, J., Sun, Y., Zeng, T., Li, Z., Zhou, T., Deng, Y., Ye, C., Li, G., & Yin, Y. (2026). CRISPR-AsCas12a with crRNA-Free Collateral Cleavage Activity for Electrochemical Diagnosis of HER2-Positive Breast Cancer. ACS Sensors. https://doi.org/10.1021/acssensors.6c03688
Vancouver
Wu S, Xu J, Sun Y, Zeng T, Li Z, Zhou T, et al. CRISPR-AsCas12a with crRNA-Free Collateral Cleavage Activity for Electrochemical Diagnosis of HER2-Positive Breast Cancer. ACS Sensors. 2026. doi:10.1021/acssensors.6c03688
BibTeX
@article{Wu2026,
author = {Wu, Shuai and Xu, Jialin and Sun, Yanting and Zeng, Tianyu and Li, Zeying and Zhou, Tianci and Deng, Ying and Ye, Chang and Li, Genxi and Yin, Yongmei},
title = {CRISPR-AsCas12a with crRNA-Free Collateral Cleavage Activity for Electrochemical Diagnosis of HER2-Positive Breast Cancer},
journal = {ACS Sensors},
year = {2026},
doi = {10.1021/acssensors.6c03688}
}
EUVIMED